清创酶作为标准早期手术切除辅助手段在人类烧伤中的临床价值:系统综述
结果显示胶原酶对TBSA低于25%的烧伤有效,Nexobrid对深度烧伤有效且减少植皮比例,菠萝蛋白酶可能减少手术清创次数或植皮面积,但证据有限。手术切除仍是烧伤清创的标准治疗。
要点
- 胶原酶对TBSA低于25%的烧伤有效,尤其适用于门诊患者。
- Nexobrid对深度烧伤有效,可减少植皮比例且无显著不良反应。
- 菠萝蛋白酶可能作为辅助治疗减少手术清创次数或植皮面积。
核心结论
- 手术切除仍是烧伤创面清创的标准治疗。
- 酶清创尤其是菠萝蛋白酶可能作为辅助治疗减少手术清创次数或植皮面积。
- 需要更大样本量且利益冲突更少的研究来明确菠萝蛋白酶的确切作用。
研究设计与样本
- 系统综述,检索CINAHL、PubMed、Ovid Medline、Web of Science、Google Scholar和Embase数据库,时间范围为1969年1月至2019年2月。
- 研究方案注册于PROSPERO注册中心。
主要发现
- 胶原酶被报道对TBSA低于25%的烧伤有效,尤其适用于门诊诊所。
- Nexobrid被显示对深度烧伤有效,并减少植皮百分比且无显著不良反应。
- 没有足够证据支持木瓜蛋白酶、Sutilains、尿素等的临床价值。
关键数值与推荐
- 胶原酶:对TBSA低于25%的烧伤有效,尤其适用于门诊诊所。
- Nexobrid:对深度烧伤有效,减少植皮百分比且无显著不良反应。
- 菠萝蛋白酶:可能帮助减少手术清创次数或植皮面积作为辅助治疗。
- 木瓜蛋白酶、Sutilains、尿素等:没有足够证据支持其临床价值。
临床怎么用
- 手术切除仍应作为烧伤创面清创的标准治疗。
- 对于TBSA低于25%的烧伤,尤其是门诊患者,可考虑胶原酶作为辅助清创。
- 对于深度烧伤,Nexobrid可作为辅助治疗以减少植皮需求。
- 菠萝蛋白酶可能作为辅助治疗减少手术清创次数或植皮面积,但需更多研究明确其作用。
局限性
- 需要更大样本量和利益冲突更少的研究来明确菠萝蛋白酶的确切作用。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
Burns are a significant public health burden worldwide. In addition to those who die, millions remain with life-threatening deformities and disabilities resulting in stigma and rejection. Surgical excision is currently the standard of care for removing necrotic tissues in burn wounds to prepare the wound bed for grafting or enhancing the healing process. However, there is a growing interest on enzymatic debridement as an adjunct therapy in burn wounds. The aim of this study was to investigate clinical trials using debriding agents for burn wound in humans in a systematic review. This was a systematic review of electronic databases including CINAHL, PubMed, Ovid Medline, Web of Science, Google Scholar, and Embase from January 1969 to February 2019. The study protocol was registered in PROSPERO registry. The following keywords were searched: "burn wounds", "enzymatic debridement", "papain", "papain-urea", "pine apple", "Bromelain", "collagenases", "Nexobrid", "Debrase", "Debridase", "Actinidia deliciosa", "Sutilains", "Debrace", "piruvat acid". Those studies fulfilling the inclusion and exclusion criteria with low score of bias based on Cochrane Bias Tool were reviewed. Sixteen investigations fulfilled our inclusion criteria to be reviewed. Six, seven, and three clinical trials on humans were found regarding collagenase, bromelain, and miscellaneous agents. Collagenase has been reported to be effective in burns below 25% of TBSA, especially in outpatients' clinics. However, Nexobrid has been shown to be effective in deep burns and decreases the percentage of graft without significant adverse effects. There was not enough evidence supporting the clinical values of Papain, Sutilains, Urea, etc. Surgical excision still remains the standard of care for burn wounds debridement. However, enzymatic debridement, especially Bromelain might help to reduce sessions for surgical debridement or area under graft as an adjunct treatment. Despite the fact, more studies with larger sample sizes and with less conflicts of interest are needed to clearly elucidate the exact role of Bromelain.
引用
- Salehi SH, Momeni M, Vahdani M, et al. Clinical Value of Debriding Enzymes as an Adjunct to Standard Early Surgical Excision in Human Burns: A Systematic Review. J Burn Care Res. 2020. PMID: 32424404. doi:10.1093/jbcr/iraa074
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。